Retrieve available abstracts of 37 articles: HTML format
Single Articles
June 2025
NDEMBI N, Mutesa L, Muvunyi CM, Kim JH, et al Bridging the vaccine divide.
Nat Med. 2025 Jun 2. doi: 10.1038/s41591-025-03728. PubMed
May 2025
O'LEARY K Measles to become endemic in the USA if vaccination rates continue to fall.
Nat Med. 2025 May 14. doi: 10.1038/d41591-025-00031. PubMed
PEREZ-ESTIGARRIBIA PE, Ribeiro Dos Santos G, Cauchemez S, Vazquez C, et al Modeling the impact of vaccine campaigns on the epidemic transmission dynamics of
chikungunya virus outbreaks.
Nat Med. 2025 May 1. doi: 10.1038/s41591-025-03684. PubMedAbstract available
GARRETSON TA, Liu J, Li SH, Scher G, et al Immune history shapes human antibody responses to H5N1 influenza viruses.
Nat Med. 2025;31:1454-1458. PubMedAbstract available
April 2025
O'LEARY K Antibiotics reduce vaccine responses in infants.
Nat Med. 2025 Apr 30. doi: 10.1038/d41591-025-00028. PubMed
HOU Z, Wu Z, Qu Z, Gong L, et al A vaccine chatbot intervention for parents to improve HPV vaccination uptake
among middle school girls: a cluster randomized trial.
Nat Med. 2025 Apr 7. doi: 10.1038/s41591-025-03618. PubMedAbstract available
March 2025
RUDMAN SPERGEL AK, Ananworanich J, Guo R, Deng W, et al mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine in healthy
adults: a phase 1/2 trial.
Nat Med. 2025 Mar 18. doi: 10.1038/s41591-025-03591. PubMedAbstract available
ADAMU AA, Ndwandwe D, Wiysonge CS Leveraging implementation science in clinical trials of vaccines in the global
south.
Nat Med. 2025 Mar 5. doi: 10.1038/s41591-025-03546. PubMed
January 2025
DU Z, Pandey A, Moghadas SM, Bai Y, et al Impact of RSVpreF vaccination on reducing the burden of respiratory syncytial
virus in infants and older adults.
Nat Med. 2025 Jan 9. doi: 10.1038/s41591-024-03431. PubMedAbstract available
GOSWAMI D, Kappe SHI Setting sights on a single-shot malaria vaccine.
Nat Med. 2025 Jan 3. doi: 10.1038/s41591-024-03427. PubMed
October 2024
WAIRAGKAR N, Ismail AJ, Abouhussein DMN, Adeyeye MC, et al Regulatory reforms will boost African vaccine production and access.
Nat Med. 2024 Oct 29. doi: 10.1038/s41591-024-03314. PubMed
Lassa vaccines to save lives, spare economies and assist in pandemic
preparedness.
Nat Med. 2024 Oct 11. doi: 10.1038/s41591-024-03332. PubMed
September 2024
NGUYEN DC, Hentenaar IT, Morrison-Porter A, Solano D, et al SARS-CoV-2-specific plasma cells are not durably established in the bone marrow
long-lived compartment after mRNA vaccination.
Nat Med. 2024 Sep 27. doi: 10.1038/s41591-024-03278. PubMedAbstract available
WEBBY RJ The practical longevity of stockpiled A(H5N1) influenza vaccine.
Nat Med. 2024 Sep 26. doi: 10.1038/s41591-024-03256. PubMed
August 2024
JOHANSEN ND, Vaduganathan M, Bhatt AS, Modin D, et al Electronic nudges for sustained influenza vaccination uptake in older adults: the
nationwide randomized NUDGE-FLU-2 trial.
Nat Med. 2024 Aug 30. doi: 10.1038/s41591-024-03202. PubMedAbstract available
SMITH DRM, Turner J, Fahr P, Attfield LA, et al Health and economic impacts of Lassa vaccination campaigns in West Africa.
Nat Med. 2024 Aug 28. doi: 10.1038/s41591-024-03232. PubMedAbstract available
DEREJE N, Fallah MP, Ndembi N, Duga A, et al A community engagement framework to accelerate the uptake of malaria vaccines in
Africa.
Nat Med. 2024 Aug 22. doi: 10.1038/s41591-024-03193. PubMed
July 2024
SUN K, Bhiman JN, Tempia S, Kleynhans J, et al SARS-CoV-2 correlates of protection from infection against variants of concern.
Nat Med. 2024 Jul 26. doi: 10.1038/s41591-024-03131. PubMedAbstract available
TAQUET M, Dercon Q, Todd JA, Harrison PJ, et al The recombinant shingles vaccine is associated with lower risk of dementia.
Nat Med. 2024 Jul 25. doi: 10.1038/s41591-024-03201. PubMedAbstract available
KHURANA S, King LR, Manischewitz J, Posadas O, et al Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly
pathogenic H5N1 clade 2.3.4.4b influenza virus.
Nat Med. 2024 Jul 16. doi: 10.1038/s41591-024-03189. PubMedAbstract available
MAY M How mRNA is powering a personalized vaccine revolution.
Nat Med. 2024 Jul 15. doi: 10.1038/d41591-024-00052. PubMed
XU H, Zou K, Dent J, Wiens KE, et al Author Correction: Enhanced cholera surveillance to improve vaccination campaign
efficiency.
Nat Med. 2024 Jul 9. doi: 10.1038/s41591-024-03176. PubMed
June 2024
ZHONG Y, Kang AYH, Tay CJX, Li HE, et al Publisher Correction: Correlates of protection against symptomatic SARS-CoV-2 in
vaccinated children.
Nat Med. 2024 Jun 10. doi: 10.1038/s41591-024-03107. PubMed
LI R, Shah PH, Stewart TF, Nam JK, et al Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive
non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
Nat Med. 2024 Jun 6. doi: 10.1038/s41591-024-03025. PubMedAbstract available
LAZARUS JV, White TM, Wyka K, Ratzan SC, et al Influence of COVID-19 on trust in routine immunization, health information
sources and pandemic preparedness in 23 countries in 2023.
Nat Med. 2024;30:1559-1563. PubMedAbstract available
CLIFF M, Welaga P, Mohammed N, Ansah P, et al Strategies for controlling pneumococcal disease and outbreaks during humanitarian
emergencies.
Nat Med. 2024;30:1515-1516. PubMed
May 2024
MENTZER AJ, Dilthey AT, Pollard M, Gurdasani D, et al High-resolution African HLA resource uncovers HLA-DRB1 expression effects
underlying vaccine response.
Nat Med. 2024 May 13. doi: 10.1038/s41591-024-02944. PubMedAbstract available
April 2024
ZHONG Y, Kang AYH, Tay CJX, Li HE, et al Correlates of protection against symptomatic SARS-CoV-2 in vaccinated children.
Nat Med. 2024 Apr 30. doi: 10.1038/s41591-024-02962. PubMedAbstract available
SARAF A, Gurjar R, Kaviraj S, Kulkarni A, et al An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase
2/3 randomized trial.
Nat Med. 2024 Apr 18. doi: 10.1038/s41591-024-02955. PubMedAbstract available
ARNOLD C 'Inverse vaccines' could treat autoimmune disease - from multiple sclerosis to
celiac disease.
Nat Med. 2024 Apr 10. doi: 10.1038/d41591-024-00024. PubMed
YARCHOAN M, Gane EJ, Marron TU, Perales-Linares R, et al Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular
carcinoma: a phase 1/2 trial.
Nat Med. 2024 Apr 7. doi: 10.1038/s41591-024-02894. PubMedAbstract available
Systematic testing in cholera surveillance enhances vaccine impact and
cost-effectiveness.
Nat Med. 2024 Apr 3. doi: 10.1038/s41591-024-02907. PubMed
March 2024
O'LEARY K Going the extra mile to increase vaccine uptake.
Nat Med. 2024 Mar 28. doi: 10.1038/d41591-024-00022. PubMed
RAPPAPORT AR, Kyi C, Lane M, Hart MG, et al A shared neoantigen vaccine combined with immune checkpoint blockade for advanced
metastatic solid tumors: phase 1 trial interim results.
Nat Med. 2024 Mar 27. doi: 10.1038/s41591-024-02851. PubMedAbstract available
XU H, Zou K, Dent J, Wiens KE, et al Enhanced cholera surveillance to improve vaccination campaign efficiency.
Nat Med. 2024 Mar 5. doi: 10.1038/s41591-024-02852. PubMedAbstract available
February 2024
PERETTI-WATEL P, Verger P, Ward JK To understand mRNA vaccine hesitancy, stop calling the public anti-science.
Nat Med. 2024 Feb 27. doi: 10.1038/s41591-024-02816. PubMed